Reducing signs of aging and increasing lifespan by drug synergy

Area of Science:

• Gerontology and molecular biology
• Cellular and molecular mechanisms of aging

Background:

• Aging is a significant risk factor for disease incidence, increasing suffering and economic burden.
• Understanding aging pathways offers potential for pharmacological interventions to extend healthspan and lifespan.
• Previous research highlights the role of target of rapamycin complex 1 (TORC1) and sphingolipid synthesis in aging.

Purpose of the Study:

• To investigate a novel pharmacological strategy for reducing aging signs and increasing lifespan.
• To evaluate the synergistic effects of combining rapamycin and myriocin on aging processes.
• To identify key cellular pathways modulated by this drug combination.

Main Methods:

• Utilized the budding yeast Saccharomyces cerevisiae as a model organism.
• Administered low-dose rapamycin to inhibit target of rapamycin complex 1 (TORC1) activity.
• Administered myriocin to inhibit sphingolipid synthesis.

Main Results:

• The combination therapy reduced signs of aging in yeast.
• A synergistic increase in lifespan was observed with the combined treatment.
• Enhanced autophagy, genomic stability, mitochondrial function, and AMP kinase pathway activity were noted.
• These improvements are linked to evolutionarily conserved pathways vital for health and longevity.

Conclusions:

• A novel pharmacological strategy combining rapamycin and myriocin shows promise in combating aging.
• This approach synergistically enhances cellular health and extends lifespan in a model organism.
• Findings suggest potential for developing human therapies to reduce age-related disease incidence and improve healthspan.